Limits...
Airway inflammation and allergen specific IgE production may persist longer than airway hyperresponsiveness in mice.

Chang YS, Kim YK, Kim TB, Kang HR, Kim SS, Bahn JW, Min KU, Kim YY, Cho SH - J. Korean Med. Sci. (2004)

Bottom Line: Each group of mice was rechallenged at 5, 7, 9, or 12 weeks after the initial challenge.Airway eosinophilia, airway inflammation and serum ovalbumin-specific IgE production persisted upon secondary allergen challenges at least 12 weeks after the initial challenge.However, airway hyperresponsiveness persisted only until mice were rechallenged 7 weeks after the initial challenge.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul 110-744, Korea.

ABSTRACT
During the preclinical study of new therapeutic modality, we evaluate whether the treatment can reverse the established asthma phenotypes in animal model. However, few have reported on the long term persistence of asthma phenotypes upon re-challenge with allergen (secondary challenge) in animal model. We evaluated the persistence of asthma phenotypes by secondary challenge at different times in previously challenged murine asthma model. BALB/c mice sensitized by intraperitoneal injections of 20 micro g of ovalbumin and 1 mg of alum on days 1 and 14 were challenged initially by the inhalation of 1% ovalbumin for 30 min on days 21, 22, and 23. Each group of mice was rechallenged at 5, 7, 9, or 12 weeks after the initial challenge. Airway hyperresponsiveness, BAL fluid, airway histology and serum ovalbumin-specific IgE level were evaluated. Airway eosinophilia, airway inflammation and serum ovalbumin-specific IgE production persisted upon secondary allergen challenges at least 12 weeks after the initial challenge. However, airway hyperresponsiveness persisted only until mice were rechallenged 7 weeks after the initial challenge. Airway inflammation and allergen specific IgE production may persist longer than airway hyperresponsiveness in a mouse asthma model of secondary allergen challenge.

Show MeSH

Related in: MedlinePlus

Experimental protocols for sensitization, initial challenge and secondary challenge. 7-week old female BALB/c mice were used for the experiment. Mice were sensitized by intraperitoneal injection and initial provocative challenge was done on days 21, 22, 23 (0 week). Secondary challenges were performed at 5, 7, 9, or 12 weeks after the initial challenge. PBS treated mice were used as controls. Five mice were used in each group. IP: intraperitoneal injection.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2822266&req=5

Figure 1: Experimental protocols for sensitization, initial challenge and secondary challenge. 7-week old female BALB/c mice were used for the experiment. Mice were sensitized by intraperitoneal injection and initial provocative challenge was done on days 21, 22, 23 (0 week). Secondary challenges were performed at 5, 7, 9, or 12 weeks after the initial challenge. PBS treated mice were used as controls. Five mice were used in each group. IP: intraperitoneal injection.

Mentions: The protocol used for sensitization and bronchial challenge was the same as previously described (5). There were five groups and each group consists of five mice; mice initially challenged, mice initially challenged and rechallenged at 5, 7, 9, or 12 weeks after the initally challenge (Fig. 1). Mice were sensitized by intraperitoneal injections of 20 µg of ovalbumin (OVA, ICN, Costa Mesa, U.S.A.) with 1 mg of alum hydroxide (alum, Sigma, St. Louis, U.S.A.) on days 1 and 14. The initial inhalation challenge was done with 1% OVA for 30 min daily on days 21, 22 and 23 with an ultrasonic nebulizer (NE-U12, Omron, Japan). Each group of mice were rechallenged at different times (5, 7, 9, or 12 weeks after the initial challenge) with 1% OVA for 30 min daily and for 3 consecutive days. Mice sensitized and challenged by PBS at each time were used as negative controls for possible environmental factors.


Airway inflammation and allergen specific IgE production may persist longer than airway hyperresponsiveness in mice.

Chang YS, Kim YK, Kim TB, Kang HR, Kim SS, Bahn JW, Min KU, Kim YY, Cho SH - J. Korean Med. Sci. (2004)

Experimental protocols for sensitization, initial challenge and secondary challenge. 7-week old female BALB/c mice were used for the experiment. Mice were sensitized by intraperitoneal injection and initial provocative challenge was done on days 21, 22, 23 (0 week). Secondary challenges were performed at 5, 7, 9, or 12 weeks after the initial challenge. PBS treated mice were used as controls. Five mice were used in each group. IP: intraperitoneal injection.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2822266&req=5

Figure 1: Experimental protocols for sensitization, initial challenge and secondary challenge. 7-week old female BALB/c mice were used for the experiment. Mice were sensitized by intraperitoneal injection and initial provocative challenge was done on days 21, 22, 23 (0 week). Secondary challenges were performed at 5, 7, 9, or 12 weeks after the initial challenge. PBS treated mice were used as controls. Five mice were used in each group. IP: intraperitoneal injection.
Mentions: The protocol used for sensitization and bronchial challenge was the same as previously described (5). There were five groups and each group consists of five mice; mice initially challenged, mice initially challenged and rechallenged at 5, 7, 9, or 12 weeks after the initally challenge (Fig. 1). Mice were sensitized by intraperitoneal injections of 20 µg of ovalbumin (OVA, ICN, Costa Mesa, U.S.A.) with 1 mg of alum hydroxide (alum, Sigma, St. Louis, U.S.A.) on days 1 and 14. The initial inhalation challenge was done with 1% OVA for 30 min daily on days 21, 22 and 23 with an ultrasonic nebulizer (NE-U12, Omron, Japan). Each group of mice were rechallenged at different times (5, 7, 9, or 12 weeks after the initial challenge) with 1% OVA for 30 min daily and for 3 consecutive days. Mice sensitized and challenged by PBS at each time were used as negative controls for possible environmental factors.

Bottom Line: Each group of mice was rechallenged at 5, 7, 9, or 12 weeks after the initial challenge.Airway eosinophilia, airway inflammation and serum ovalbumin-specific IgE production persisted upon secondary allergen challenges at least 12 weeks after the initial challenge.However, airway hyperresponsiveness persisted only until mice were rechallenged 7 weeks after the initial challenge.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul 110-744, Korea.

ABSTRACT
During the preclinical study of new therapeutic modality, we evaluate whether the treatment can reverse the established asthma phenotypes in animal model. However, few have reported on the long term persistence of asthma phenotypes upon re-challenge with allergen (secondary challenge) in animal model. We evaluated the persistence of asthma phenotypes by secondary challenge at different times in previously challenged murine asthma model. BALB/c mice sensitized by intraperitoneal injections of 20 micro g of ovalbumin and 1 mg of alum on days 1 and 14 were challenged initially by the inhalation of 1% ovalbumin for 30 min on days 21, 22, and 23. Each group of mice was rechallenged at 5, 7, 9, or 12 weeks after the initial challenge. Airway hyperresponsiveness, BAL fluid, airway histology and serum ovalbumin-specific IgE level were evaluated. Airway eosinophilia, airway inflammation and serum ovalbumin-specific IgE production persisted upon secondary allergen challenges at least 12 weeks after the initial challenge. However, airway hyperresponsiveness persisted only until mice were rechallenged 7 weeks after the initial challenge. Airway inflammation and allergen specific IgE production may persist longer than airway hyperresponsiveness in a mouse asthma model of secondary allergen challenge.

Show MeSH
Related in: MedlinePlus